Previous 10 | Next 10 |
ChemoCentryx (NASDAQ: CCXI) develops drugs for orphan diseases, meaning those with fewer than 200,000 patients in the U.S. Currently, ChemoCentryx has four drug candidates in development with the most advanced being avacopan. This quarter, ChemoCentryx will announce pivotal trial results wit...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
MOUNTAIN VIEW, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET in New York City. Key therapeutic areas of focus for the R&D Day will be ANCA-Associate...
ChemoCentryx, Inc. ( CCXI ) is a small-cap biopharmaceutical company developing new chemokine and chemoattractant systems and medications for inflammatory and autoimmune diseases and cancer. The company’s current focus is on its late stage drug candidates for patients with rare diseases...
The Sell-Off ChemoCentryx ( CCXI ) is a clinical-stage small market cap ($390M) biopharma developing innovative chemokine-based therapeutics for rare, autoimmune and oncological diseases. Since my last article in late May/2019, CCXI share price has depreciated 50%. The stock price deprecia...
ChemoCentryx ( CCXI -16.3% ) slumps after releasing less-than-expected Q2 results yesterday after the close. More news on: ChemoCentryx, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Gainers: EverQuote (NASDAQ: EVER ) +47% . NeoPhotonics Corporation (NYSE: NPTN ) +27% . Invacare Corporation (NYSE: IVC ) +23% . Adient plc (NYSE: ADNT ) +23% . Ducommun Incorporated (NYSE: DCO ) +22% . Insulet Corporation (NASDAQ: PODD ) +19% . Greenlight Capital Re (NASDAQ: G...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2019 Q2 earnings Read more ...
ChemoCentryx, Inc. (NASDAQ: CCXI ): Q2 GAAP EPS of -$0.26 misses by $0.04 . More news on: ChemoCentryx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 -- -- Completed enrollment in LUMINA 1 Phase II trial of CCR2 inhibitor CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Advancing three additi...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...